Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
therapeutic autologous dendritic cells + pneumococcal 13-valent conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Intramuscular
01
Overview
This investigational combination immunotherapy, developed by the Mayo Clinic, consists of autologous dendritic cells and the pneumococcal 13-valent conjugate vaccine (Prevnar 13). It is being evaluated for the treatment of unresectable primary liver cancers, specifically hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). The treatment strategy involves harvesting a patient's white blood cells to generate dendritic cells, which are then cultured in a laboratory and injected intratumorally to stimulate an immune response against tumor antigens. Prevnar 13 is administered intramuscularly as an adjuvant to further boost the immune system's activity. This regimen is typically applied following high-dose external beam radiotherapy and is often combined with immune checkpoint inhibitors like atezolizumab and bevacizumab to overcome tumor-mediated immunosuppression and enhance anti-tumor immune responses.
- Brand names
- Prevnar 13Prevnar13Prevnar-13
- Other names
- pneumococcal 13-valent conjugate vaccine-Mayo Clinic-hepatocellular carcinoma-intrahepatic cholangiocarcinomapneumococcal13-valent conjugate vaccine-Mayo Clinic-hepatocellular carcinoma-intrahepatic cholangiocarcinomapneumococcal-13-valent conjugate vaccine-Mayo Clinic-hepatocellular carcinoma-intrahepatic cholangiocarcinomaautologous dendritic cells and Prevnarautologous dendritic cells and pneumococcal 13-valent conjugate vaccine
Beyond the preview
Go deeper on therapeutic autologous dendritic cells + pneumococcal 13-valent conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on therapeutic autologous dendritic cells + pneumococcal 13-valent conjugate vaccine.